IMP17307 / IMPACT Therap, Eikon Therap - LARVOL DELTA

A first-in-human Phase 1/2 study of EIK1004, a PARP1-selective CNS-penetrant inhibitor, in patients with advanced solid tumors with HRR mutations (ESMO 2026) - No abstract available

Clinical • First-in-human • Metastases • P1/2 data • Oncology • Solid Tumor

Presentations to cover updates across Eikon’s clinical pipeline including: (GlobeNewswire) - "Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and chemotherapy in stage 4 non-small cell lung cancer (NSCLC); Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors; Initial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer; Initial results from an ongoing Phase 1/2 study of EIK1004, a highly selective CNS-penetrant PARP1 inhibitor in advanced solid malignancies."

Clinical data • Non Small Cell Lung Cancer • Prostate Cancer

A first-in-human (FIH), Phase 1/2, dose-escalation and dose-optimization study of central nervous system (CNS)-penetrant, PARP1-selective inhibitor EIK1004 in patients with advanced solid tumors with or without brain metastases (AACR 2026) - P1/2 | "Part 2 will open once the RDE is determined from Part 1. This study opened on 23-Jan-2025 and is actively enrolling participants."

Clinical • First-in-human • Metastases • P1/2 data • Brain Cancer • CNS Tumor • Oncology • Pancreatic Cancer • Solid Tumor • BRCA1 • BRCA2 • HRD • PARP2

Identification of EIK1004 (IMP1707), a CNS-penetrant, potent, and selective PARP1 inhibitor poised for testing in patients with HRD mutant tumors (AACR 2025) - "EIK1004 potently and selectively inhibits and traps PARP1, with downstream activity in cells and mouse models. EIK1004 exhibits robust pharmacokinetic properties including brain penetration, high bioavailability across preclinical species, and a safety profile that supports further development. EIK1004 is currently being evaluated in a Phase 1 clinical trial in solid tumors with or without brain metastasis."

Clinical • Brain Cancer • Breast Cancer • CNS Tumor • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA1 • BRCA2 • HRD • PARP2

Recent Program Milestones (Businesswire) - "(i) EIK1001-006 (TeLuRide-006, NCT06697301): The first patient has been enrolled in the TeLuRide-006 trial, which is investigating the potential role of EIK1001, a systemically administered co-agonist of toll-like receptors 7 and 8 that has been observed to exhibit clinical activity as a monotherapy and in combination with anti-PD-(L)1 agents across multiple solid tumor types in Phase 1 trials, as an addition to standard of care pembrolizumab (KEYTRUDA) for the treatment of patients with advanced metastatic melanoma...; (ii) EIK1004-001 (NCT06907043): The first patient has been dosed in a Phase 1/2 trial of EIK1004, a CNS-penetrant selective PARP1 inhibitor."

Trial status • Melanoma

EIK1004-001: A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. (clinicaltrials.gov) - P1/2 | N=130 | Recruiting | Sponsor: Eikon Therapeutics | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2030 ➔ Dec 2028 | Trial primary completion date: Dec 2026 ➔ Dec 2028

Enrollment open • Monotherapy • Trial completion date • Trial primary completion date • Solid Tumor

EIK1004-001: A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. (clinicaltrials.gov) - P1/2 | N=130 | Not yet recruiting | Sponsor: Eikon Therapeutics

New P1/2 trial • Oncology • Solid Tumor

Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline (Businesswire) - "Eikon Therapeutics, Inc...announced the initial closing of a $350.7 million Series D financing. Since its founding in 2019, Eikon Therapeutics has privately raised in excess of $1.1 billion to support its mission of developing new medicines to address grievous illnesses....Eikon’s clinical portfolio is anchored by its lead program, EIK1001, a systemically administered co-agonist of toll-like receptors 7 and 8 now in a Phase III trial for advanced melanoma.... In parallel, the company is advancing EIK1003, a highly selective PARP1 inhibitor currently undergoing Phase 1 evaluation in patients with breast, ovarian, prostate, or pancreatic cancers, and EIK1004, a central nervous system-penetrant PARP1-selective inhibitor poised to initiate Phase 1 studies targeting brain cancers. Eikon’s early-stage pipeline features, among other undisclosed candidates, two androgen receptor antagonists and an internally derived WRN inhibitor (EIK1005)..."

Financing • Brain Cancer • Breast Cancer • Melanoma • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer

Eikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference (Businesswire) - "IND-enabling Studies Begin for Brain-Penetrant PARP1 Inhibitor, IMP17307: Collaborating with Impact Therapeutics, Eikon has initiated IND-enabling studies for a brain-penetrant PARP1 candidate and is planning for a Phase 1 clinical trial in 2025. Discovery Pipeline Progress: Using its proprietary platform, Eikon is conducting lead optimization for several programs including those targeting the androgen receptor and its clinically relevant variants, as well as several targeting key proteins in the DNA damage repair pathway including Werner (WRN). The company anticipates nominating a new clinical candidate in early 2024."

New molecule • New P1 trial • Oncology

Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors (PRNewswire) - "IMPACT Therapeutics...and Eikon Therapeutics...announced that the companies have entered into a global license and collaboration agreement for PARP1 selective inhibitors including IMP1734, which is anticipated to enter into Phase I clinical study in 2023. Under the collaboration agreement, Eikon received an exclusive license from Impact to co-develop, register, manufacture, and commercialize IMP1734 and other PARP1 selective inhibitors globally, excluding Greater China (mainland China, Hong Kong, Macau, and Taiwan)."

Licensing / partnership • New P1 trial • Oncology